We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 234

Court finds patent indefiniteness in unobtrusive claims

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 15 2014

In Interval Licensing LLC v. AOL, Inc., the Federal Circuit applied the test for patent indefiniteness set forth in the recent Supreme Court decision

A look at the Myriad gene patent claims and the USPTO memo to examiners on Myriad

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • June 17 2013

Now that the Supreme Court has issued its decision in the "ACLUMyriad" gene patents case (Association for Molecular Pathology v. Myriad Genetics

Humira patent invalid for obviousness type double patenting

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court's finding that a second patent covering

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Federal Circuit clears way for generic Yasmin

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 26 2012

In Bayer Schering Pharma AG v. Lupin, Ltd., the Federal Circuit upheld the district court’s determination that the Abbreviated New Drug Applications at issue did not infringe the asserted patent related to Yasmin

USPTO asks for patent subject matter eligibility comments by July 31, 2014

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • June 30 2014

In a June 30, 2014 Federal Register Notice, the USPTO requested public comments by July 31, 2014 on patent subject matter eligibility under the

Federal Circuit upholds validity of Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 28 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Myriad sues Ambry for offering BRCA1BRCA2 breast cancer genetic testing

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 11 2013

On July 9, 2013, Myriad Genetics, Inc. brought suit against Ambry Genetics Corporation, alleging that Ambry is infringing ten (10) patents by

Supreme Court oral arguments in ACLU Myriad gene patent case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 15 2013

On April 15, 2013, the Supreme Court heard oral arguments in one of the most controversial and publicized biotech patent cases-the "ACLUMyriad" gene

Comments on patent subject matter eligibility guidance due by July 31

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 28 2014

This week brings the July 31, 2014 deadline for submitting written comments on two USPTO patent subject matter eligibility guidance documents: The